1019201-53-6

Basic information

• Product Name: 2-(trifluoroMethyl)isonicotinoyl chloride
• Synonyms: 2-(trifluoroMethyl)isonicotinoyl chloride
• CAS NO: 1019201-53-6
• Molecular Formula: C₇H₃ClF₃NO
• Molecular Weight: 209.5530296
• Mol File: 1019201-53-6.mol
• Article Data: 2

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 2-(trifluoroMethyl)isonicotinoyl chloride(CAS DataBase Reference)
• NIST Chemistry Reference: 2-(trifluoroMethyl)isonicotinoyl chloride(1019201-53-6)
• EPA Substance Registry System: 2-(trifluoroMethyl)isonicotinoyl chloride(1019201-53-6)

Safety Data

• Hazardous Substances Data: 1019201-53-6(Hazardous Substances Data)

Usage

Molecular weight

201.55 g/mol
Derivative of isonicotinoyl chloride
Used in organic synthesis and as a reagent for introducing the isonicotinoyl group into various compounds
Trifluoromethyl substituent makes it useful in pharmaceutical and agrochemical applications
Reactive compound
Handled and stored under inert gas to avoid exposure to air or moisture
Potential for generating toxic or corrosive byproducts
Important in medicinal chemistry and drug development
Valuable in the synthesis of biologically active molecules

Upstream product

• 131747-41-6 2-(trifluoromethyl)-4-pyridinecarboxylic acid 

Downstream Products

• 916210-02-1 2-(trifluoromethyl)pyridine-4-carbonitrile 

Relevant articles and documents

Discovery of the First Orally Available, Selective KNa1.1 Inhibitor: In Vitro and in Vivo Activity of an Oxadiazole Series

The gene KCNT1 encodes the sodium-activated potassium channel KNa1.1 (Slack, Slo2.2). Variants in the KCNT1 gene induce a gain-of-function (GoF) phenotype in ionic currents and cause a spectrum of intractable neurological disorders in infants and children, including epilepsy of infancy with migrating focal seizures (EIMFS) and autosomal dominant nocturnal frontal lobe epilepsy (ADNFLE). Effective treatment options for KCNT1-related disease are absent, and novel therapies are urgently required. We describe the development of a novel class of oxadiazole KNa1.1 inhibitors, leading to the discovery of compound 31 that reduced seizures and interictal spikes in a mouse model of KCNT1 GoF.